Nationwide surveillance of antimicrobial resistance in invasive isolates of Streptococcus pneumoniae in Taiwan from 2017 to 2019
Copyright © 2021. Published by Elsevier B.V..
BACKGROUND/PURPOSE: Streptococcus pneumoniae causes pneumonia and other invasive diseases, and is a leading cause of mortality in the elderly population. The present study aimed to provide current antimicrobial resistance and epidemiological profiles of S. pneumoniae infections in Taiwan.
METHODS: A total of 252 nonduplicate S. pneumoniae isolates were collected from patients admitted to 16 hospitals in Taiwan between January 2017 and December 2019, and were analyzed. The minimum inhibitory concentration of antibiotics was determined using the Vitek 2 automated system for antimicrobial susceptibility testing. Furthermore, epidemiological profiles of S. pneumoniae infections were analyzed.
RESULTS: Among the strains analyzed, 88% were recognized as invasive pneumococcal strains. According to the Clinical and Laboratory Standards Institute criteria for non-meningitis, the prevalence of penicillin-non-susceptible S. pneumoniae demonstrated a declining trend from 43.6% in 2017 to 17.2% in 2019. However, the rate of penicillin-non-susceptible S. pneumoniae was 85.7% based on the criteria for meningitis. Furthermore, the prevalence of ceftriaxone-non-susceptible S. pneumoniae was 62.7% based on the criteria for meningitis. Isolates demonstrated higher susceptibility toward doripenem and ertapenem than toward meropenem and imipenem. An increased rate of non-susceptibility toward levofloxacin was observed in southern Taiwan (15.1%) and elderly patients (≥65 years; 11.4%). Most isolates were susceptible to vancomycin and linezolid.
CONCLUSION: Empirical treatment with ceftriaxone monotherapy for pneumococcal meningitis should be carefully monitored owing to its high non-susceptibility rate. The susceptibility rates of most isolates to penicillin (used for treating non-meningitis pneumococcal diseases), carbapenems (ertapenem and doripenem), respiratory quinolones (moxifloxacin and levofloxacin), vancomycin, and linezolid suggested the potential of these antibiotics in treating pneumococcal diseases in Taiwan.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi - 55(2022), 2 vom: 15. Apr., Seite 215-224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tsai, Yu-Te [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.04.2022 Date Revised 19.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jmii.2021.05.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327656956 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327656956 | ||
| 003 | DE-627 | ||
| 005 | 20231225201254.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jmii.2021.05.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327656956 | ||
| 035 | |a (NLM)34219043 | ||
| 035 | |a (PII)S1684-1182(21)00105-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tsai, Yu-Te |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nationwide surveillance of antimicrobial resistance in invasive isolates of Streptococcus pneumoniae in Taiwan from 2017 to 2019 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2022 | ||
| 500 | |a Date Revised 19.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND/PURPOSE: Streptococcus pneumoniae causes pneumonia and other invasive diseases, and is a leading cause of mortality in the elderly population. The present study aimed to provide current antimicrobial resistance and epidemiological profiles of S. pneumoniae infections in Taiwan | ||
| 520 | |a METHODS: A total of 252 nonduplicate S. pneumoniae isolates were collected from patients admitted to 16 hospitals in Taiwan between January 2017 and December 2019, and were analyzed. The minimum inhibitory concentration of antibiotics was determined using the Vitek 2 automated system for antimicrobial susceptibility testing. Furthermore, epidemiological profiles of S. pneumoniae infections were analyzed | ||
| 520 | |a RESULTS: Among the strains analyzed, 88% were recognized as invasive pneumococcal strains. According to the Clinical and Laboratory Standards Institute criteria for non-meningitis, the prevalence of penicillin-non-susceptible S. pneumoniae demonstrated a declining trend from 43.6% in 2017 to 17.2% in 2019. However, the rate of penicillin-non-susceptible S. pneumoniae was 85.7% based on the criteria for meningitis. Furthermore, the prevalence of ceftriaxone-non-susceptible S. pneumoniae was 62.7% based on the criteria for meningitis. Isolates demonstrated higher susceptibility toward doripenem and ertapenem than toward meropenem and imipenem. An increased rate of non-susceptibility toward levofloxacin was observed in southern Taiwan (15.1%) and elderly patients (≥65 years; 11.4%). Most isolates were susceptible to vancomycin and linezolid | ||
| 520 | |a CONCLUSION: Empirical treatment with ceftriaxone monotherapy for pneumococcal meningitis should be carefully monitored owing to its high non-susceptibility rate. The susceptibility rates of most isolates to penicillin (used for treating non-meningitis pneumococcal diseases), carbapenems (ertapenem and doripenem), respiratory quinolones (moxifloxacin and levofloxacin), vancomycin, and linezolid suggested the potential of these antibiotics in treating pneumococcal diseases in Taiwan | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antimicrobial resistance | |
| 650 | 4 | |a Nationwide surveillance | |
| 650 | 4 | |a Streptococcus pneumoniae | |
| 650 | 4 | |a Taiwan | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Penicillins |2 NLM | |
| 650 | 7 | |a Levofloxacin |2 NLM | |
| 650 | 7 | |a 6GNT3Y5LMF |2 NLM | |
| 650 | 7 | |a Vancomycin |2 NLM | |
| 650 | 7 | |a 6Q205EH1VU |2 NLM | |
| 650 | 7 | |a Ceftriaxone |2 NLM | |
| 650 | 7 | |a 75J73V1629 |2 NLM | |
| 650 | 7 | |a Doripenem |2 NLM | |
| 650 | 7 | |a BHV525JOBH |2 NLM | |
| 650 | 7 | |a Ertapenem |2 NLM | |
| 650 | 7 | |a G32F6EID2H |2 NLM | |
| 650 | 7 | |a Linezolid |2 NLM | |
| 650 | 7 | |a ISQ9I6J12J |2 NLM | |
| 700 | 1 | |a Lee, Yu-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Min-Chi |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Pei-Lan |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Po-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Shu-Hsing |e verfasserin |4 aut | |
| 700 | 1 | |a Ko, Wen-Chien |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Chi-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Ting-Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Yen, Muh-Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lih-Shinn |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chang-Pan |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Wen-Sen |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Zhi-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yao-Shen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Fu-Der |e verfasserin |4 aut | |
| 700 | 1 | |a Tseng, Shu-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Chao-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yu-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Sheng, Wang-Huei |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Chun-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Hung-Jen |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Chun-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yen-Hsu |e verfasserin |4 aut | |
| 700 | 1 | |a Hsueh, Po-Ren |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi |d 1998 |g 55(2022), 2 vom: 15. Apr., Seite 215-224 |w (DE-627)NLM104271183 |x 1995-9133 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2022 |g number:2 |g day:15 |g month:04 |g pages:215-224 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jmii.2021.05.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2022 |e 2 |b 15 |c 04 |h 215-224 | ||